192 related articles for article (PubMed ID: 21206113)
21. Optimizing the use of pneumococcal conjugate vaccine globally.
O'Brien KL
JAMA; 2013 Sep; 310(9):911-3. PubMed ID: 24002275
[No Abstract] [Full Text] [Related]
22. Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults.
Gladstone RA; Jefferies JM; Faust SN; Clarke SC
Expert Rev Vaccines; 2012 Aug; 11(8):889-902. PubMed ID: 23002969
[TBL] [Abstract][Full Text] [Related]
23. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
American Academy of Pediatrics Committee on Infectious Diseases
Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity of pneumococcal vaccine in heart transplant recipients.
Blumberg EA; Brozena SC; Stutman P; Wood D; Phan HM; Musher DM
Clin Infect Dis; 2001 Jan; 32(2):307-10. PubMed ID: 11170924
[TBL] [Abstract][Full Text] [Related]
25. [23-valent pneumococcal vaccine. Statement of the Consultive Committee of Immunizations on behalf of the Chilean Infectious Diseases Society: February 2010].
Ripoll M E; Valenzuela B MT; Vergara F R; Abarca V K; Muñoz M A; Jiménez de la Jara J; Pinto C ME; Luchsinger F V
Rev Chilena Infectol; 2010 Apr; 27(2):133-7. PubMed ID: 20556313
[TBL] [Abstract][Full Text] [Related]
26. Effect of pneumococcal polysaccharide vaccine on nonbacteremic pneumococcal pneumonia.
Weiser JN; Austrian R
Clin Infect Dis; 2007 Apr; 44(8):1139-40; author reply 1140-1. PubMed ID: 17366469
[No Abstract] [Full Text] [Related]
27. [Simultaneous vaccination against influenza and invasive pneumococcal disease in chronic dialysis patients].
Trmal J; Havlícková M; Bícová R; Bitterová Z; Kelerová J
Epidemiol Mikrobiol Imunol; 2005 Aug; 54(3):123-8. PubMed ID: 16173523
[TBL] [Abstract][Full Text] [Related]
28. Invasive bacterial diseases: national surveillance in Italy and vaccination coverage in the Local Health Agency 4 "Chiavarese", Liguria region (Italy).
Trucchi C; Zoppi G
J Prev Med Hyg; 2012 Jun; 53(2):120-4. PubMed ID: 23240174
[TBL] [Abstract][Full Text] [Related]
29. Pneumococcal conjugate vaccine for young children.
Selman S; Hayes D; Perin LA; Hayes WS
Manag Care; 2000 Sep; 9(9):49-52, 54, 56-7 passim. PubMed ID: 11116663
[TBL] [Abstract][Full Text] [Related]
30. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema.
Byington CL; Korgenski K; Daly J; Ampofo K; Pavia A; Mason EO
Pediatr Infect Dis J; 2006 Mar; 25(3):250-4. PubMed ID: 16511389
[TBL] [Abstract][Full Text] [Related]
31. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects.
Davis SM; Deloria-Knoll M; Kassa HT; O'Brien KL
Vaccine; 2013 Dec; 32(1):133-45. PubMed ID: 23684824
[TBL] [Abstract][Full Text] [Related]
32. Memory B Cell Divergences upon Immunization Against Streptococcus pneumoniae in HIV-1-Infected Adults.
Tsachouridou O; Skoura L; Zebekakis P; Margariti A; Metallidis S
AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1053-4. PubMed ID: 26535799
[No Abstract] [Full Text] [Related]
33. [Antipneumococcal vaccine: up date and prospective].
Caramia G; Pastorelli G
Minerva Pediatr; 2005 Oct; 57(5):229-41. PubMed ID: 16205607
[TBL] [Abstract][Full Text] [Related]
34. Missed opportunities in antipneumococcal vaccination. Can something more be done for prevention?
Arencibia Jiménez M; Navarro Gracia JF; Delgado de Los Reyes JA; Pérez Torregrosa G; López Parra D; López García P
Arch Bronconeumol; 2014 Mar; 50(3):93-8. PubMed ID: 24315186
[TBL] [Abstract][Full Text] [Related]
35. Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged ≤59 months---selected U.S. regions, 2010--2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Nov; 60(43):1477-81. PubMed ID: 22048728
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
[TBL] [Abstract][Full Text] [Related]
37. Serotype distribution of Streptococcus pneumoniae isolated from patients with invasive pneumococcal disease in Brazil before and after ten-pneumococcal conjugate vaccine implementation.
dos Santos SR; Passadore LF; Takagi EH; Fujii CM; Yoshioka CR; Gilio AE; Martinez MB
Vaccine; 2013 Dec; 31(51):6150-4. PubMed ID: 23747454
[TBL] [Abstract][Full Text] [Related]
38. Oral immunization with recombinant Lactococcus lactis confers protection against respiratory pneumococcal infection.
Villena J; Medina M; Raya R; Alvarez S
Can J Microbiol; 2008 Oct; 54(10):845-53. PubMed ID: 18923553
[TBL] [Abstract][Full Text] [Related]
39. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.
Isaacman DJ; McIntosh ED; Reinert RR
Int J Infect Dis; 2010 Mar; 14(3):e197-209. PubMed ID: 19700359
[TBL] [Abstract][Full Text] [Related]
40. Call to action on pneumococcal disease: review of vaccination evidence and outcomes of webcast programs.
Grogg SE; Schultz J
J Am Osteopath Assoc; 2015 Jun; 115(6 Suppl):S6-25. PubMed ID: 26000904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
